Streetbeat News

Revenues

GVA

Granite Construction has reaffirmed its 2024 revenue outlook at $3.9B-$4.0B, slightly below the $4.012B estimate. The company expects an adjusted EBITDA margin of 10%-11%, with SG&A expenses rising due to increased incentive compensation.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:54 am

KIM

Kimco Realty reported Q3 2024 earnings of $0.43 per share, surpassing the analyst estimate of $0.41. Sales reached $507.63 million, exceeding the expected $497.613 million. Both earnings and sales showed significant year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:51 am

FLWS

1-800-flowers.com projects its FY25 adjusted EBITDA to be between $85M-$95M and free cash flow to range from $45M-$55M.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:50 am

GIL

Gildan Activewear reported Q3 2024 earnings per share of $0.85, meeting analyst expectations. The company's sales were $891.1 million, surpassing the estimated $883.5 million and marking a 2.44% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:46 am

LI

Li Auto shares declined despite reporting better-than-expected Q3 results due to a disappointing Q4 revenue outlook.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:46 am

ETR

Entergy's Q3 2024 earnings per share beat estimates, but sales fell short. EPS was $2.99, slightly above the $2.97 estimate, but down from $3.27 last year. Sales were $3.389 billion, missing the $3.663 billion estimate and down from $3.596 billion last year.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:43 am

IDXX

IDEXX Laboratories has adjusted its 2024 revenue guidance to $3.865B-$3.89B, down from previous estimates, due to macroeconomic and sector challenges affecting U.S. veterinary clinics. The company expects revenue growth of 5.5%-6.2% as reported and 5.3%-6.0% organic.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:43 am

VNT

Vontier Corp anticipates Q4 2024 revenue of $770 million, slightly above estimates, with adjusted EPS in line with expectations. Core sales are expected to grow by 1.5%, but the adjusted operating profit margin is projected to decrease by 20 basis points year-over-year.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:40 am

AGIO

Agios Pharmaceuticals anticipates that its cash reserves, along with expected product revenue and interest income, will ensure financial independence. This will support potential launches of PYRUKYND, advancement of current programs, and pipeline expansion.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:40 am

BAND

Bandwidth has revised its Q4 revenue guidance to $198M-$208M, surpassing the previous estimate of $189.67M. The company also projects FY24 revenue to be between $737M and $747M.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:39 am